ABSTRACT
Abstract: Bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita are subepidermal autoimmune blistering diseases whose antigenic target is located at the basement membrane zone. Mucous membrane pemphigoid and epidermolysis bullosa acquisita can evolve with cicatricial mucosal involvement, leading to respiratory, ocular and/or digestive sequelae with important morbidity. For each of these dermatoses, a literature review covering all therapeutic options was performed. A flowchart, based on the experience and joint discussion among the authors of this consensus, was constructed to provide treatment orientation for these diseases in Brazil. In summary, in the localized, low-risk or non-severe forms, drugs that have immunomodulatory action such as dapsone, doxycycline among others may be a therapeutic option. Topical treatment with corticosteroids or immunomodulators may also be used. Systemic corticosteroid therapy continues to be the treatment of choice for severe forms, especially those involving ocular, laryngeal-pharyngeal and/or esophageal mucosal involvement, as may occur in mucous membrane pemphigoid and epidermolysis bullosa acquisita. Several immunosuppressants are used as adjuvant alternatives. In severe and recalcitrant cases, intravenous immunoglobulin is an alternative that, while expensive, may be used. Immunobiological drugs such as rituximab are promising drugs in this area. Omalizumab has been used in bullous pemphigoid.
Subject(s)
Humans , Epidermolysis Bullosa Acquisita/drug therapy , Pemphigoid, Benign Mucous Membrane/drug therapy , Pemphigoid, Bullous/drug therapy , Consensus , Prognosis , Societies, Medical , Brazil , Epidermolysis Bullosa Acquisita/diagnosis , Pemphigoid, Benign Mucous Membrane/diagnosis , Pemphigoid, Bullous/diagnosis , Adrenal Cortex Hormones/therapeutic use , Dermatology , Immunosuppressive Agents/therapeutic use , Anti-Inflammatory Agents/therapeutic useABSTRACT
Abstract: Epidermolysis bullosa acquisita is a severe autoimmune subepidermal bullous disease. In this report, we described for the first time a patient with epidermolysis bullosa acquisita who developed acute renal failure. There is a possibility that epidermolysis bullosa acquisita and acute renal failure's pathogenesis shared some common autoimmune pathways. Moreover, acute blood volume reduction may be another cause of prerenal kidney failure. Further studies are needed to verify our hypothesis.
Subject(s)
Humans , Male , Aged , Epidermolysis Bullosa Acquisita/complications , Epidermolysis Bullosa Acquisita/pathology , Acute Kidney Injury/etiology , Skin/pathology , Biopsy , Epidermolysis Bullosa Acquisita/drug therapy , Treatment Outcome , Fluorescent Antibody Technique, Direct , Acute Kidney Injury/drug therapyABSTRACT
A epidermólise bolhosa adquirida é doença bolhosa subepidérmica crônica e rara. Geralmente, inicia-se na fase adulta, sendo a etiologia desconhecida, embora vinculada à presença de anticorpos contra o colágeno tipo VII. Há formação de bolhas, espontaneamente ou após trauma, podendo causar complicações graves. O tratamento é desapontador e difícil. Além da terapia convencional com corticoides sistêmicos, recentemente, novas modalidades terapêuticas promissoras estão sendo utilizadas, dentre elas, a imunoglobulina intravenosa. Destaca-se, neste relato, o difícil manejo clínico desta doença, e a melhora importante com a imunoglobulina intravenosa.
Acquired bullous epidermolysis is a chronic and rare bullous subepidermal disease. It usually begins in adulthood and its etiology is unknown although it is associated with antibodies against type VII collagen. There are spontaneous and trauma induced formation of blisters that may cause serious complications. Treatment is disappointing and difficult. Apart from conventional therapy with systemic corticosteroid, new therapeutic modalities such as intravenous immunoglobulin are currently being used. This report highlights the extremely difficult clinical management of this rare disease and the important improvement provided by intravenous immunoglobulin.
Subject(s)
Female , Humans , Middle Aged , Epidermolysis Bullosa Acquisita/drug therapy , Immunoglobulins, Intravenous/therapeutic use , Immunologic Factors/therapeutic use , Basement Membrane/pathology , /analysis , Epidermolysis Bullosa Acquisita/diagnosis , Epidermolysis Bullosa Acquisita/pathology , Fluorescent Antibody Technique, Direct , Immunoglobulin A/analysis , Immunoglobulin G/analysis , Severity of Illness Index , Treatment OutcomeABSTRACT
Apresenta-se caso de epidermólise bolhosa adquirida inflamatória. Paciente do sexo masculino, 53 anos, há seis meses com erupção vesicobolhosa pruriginosa sobre base eritematosa no tronco, axilas e membros. O exame anatomopatológico mostrou bolha subepidérmica com neutrófilos. A imunofluorescência direta revelou depósitos lineares de IgG, IgA, IgM e C3 na zona da membrana basal, sendo a imunofluorescência indireta e o Salt Split Skin indireto negativos. Anticorpos antinucleares não reagentes. Houve melhora do quadro com prednisona e cicatrização de algumas lesões com formação de milia. Trata-se de apresentação rara de epidermólise bolhosa adquirida, com lesões iniciais predominantemente inflamatórias.
We report a case of an inflammatory variant of epidermolysis bullosa acquisita in a 53-year-old male, with itching blistering eruption on the trunk, armpits and limbs for six months. The skin biopsy specimen showed subepidermal blister with neutrophils. Direct immunofluorescence revealed linear depositions of IgG, IgA, IgM and C3 at the basement membrane; indirect immunofluorescence and salt Split Skin were negative. Antinuclear antibodies were also negative. Improvement of the blisters followed treatment with systemic corticotherapy and some lesions healed with milia. This is a rare presentation of epidermolysis bullosa acquisita, with inflammatory lesions at first.
Subject(s)
Humans , Male , Middle Aged , Epidermolysis Bullosa Acquisita/pathology , Pemphigoid, Bullous/pathology , Skin/pathology , Anti-Inflammatory Agents/therapeutic use , Biopsy , Diagnosis, Differential , Epidermolysis Bullosa Acquisita/drug therapy , Pemphigoid, Bullous/drug therapy , Prednisone/therapeutic useABSTRACT
La epidermolisis ampollar adquirida (EAA) es una enfermedad autoinmune provocada por autoanticuerpos contra el colágeno tipo VII de la sublámina densa de la dermis. Sus manifestaciones clínicas exigen especial atención para diferenciarla del lupus ampollar (LA), el penfigoide ampollar (PA) y la porfiria cutánea tarda (PCT). La clínica, la histopatología, la inmunofluorescencia directa (IFD) y la inmunofluorescencia indirecta (IFI) con la técnica de salt-split son de gran ayuda para el diagnóstico. El caso de una paciente con EAA y lupus eritematoso sistémico (LES) plantea la discusión sobre las diferencias y semejanzas entre el LA y la EAA. La presencia de mecanismos inmunopatogénicos comunes y la asociación de LES y EAA permitiría suponer que se trata de expresiones clínicas de una misma afección
Subject(s)
Humans , Adult , Female , Epidermolysis Bullosa Acquisita/diagnosis , Autoantibodies , Collagen , Epidermolysis Bullosa Acquisita/complications , Epidermolysis Bullosa Acquisita/drug therapy , Lupus Erythematosus, SystemicABSTRACT
Se presenta el caso de una paciente, de sexo femenino, de 55 años con diagnóstico clínico e inmunopatológico de epidermólisis ampollar adquirida, con compromiso extenso de mucosas, afectando hasta tercio superior de esófago. Se efectuó una revisión del tema en sus aspectos epidemiológicos, clínicos, inmunohistológicos, pronósticos y terapéuticos